IU Indianapolis ScholarWorks :: Browsing by Subject "Heart transplantation"

Browsing by Subject "Heart transplantation"

Now showing 1 - 10 of 14

A Case Report of Postheart Transplant Epicardial Adipose Deposition in a Patient With Dunnigan Syndrome
(American College of Physicians, 2022) Bajpai, Vatsal; Damera, Nihanth; Pattisapu, Anish; Oral, Elif; Bateman, Pantila; Rao, Roopa A.; Medicine, School of Medicine
Dunnigan syndrome is a rare genetic disorder that is a type of familial partial lipodystrophy. In some patients, severe cardiomyopathy and heart transplantation have been reported in this syndrome. Here, we describe a 40-year-old patient with Dunnigan syndrome who underwent heart transplantation for end-stage heart failure. Post-transplantation, routine imaging showed an accumulation of epicardial adipose tissue around the heart. In general, in Dunnigan syndrome, epicardial fat accumulation is not different compared with that of the general population. This is the first case report of exaggerated accumulation of adipose tissue around the heart causing subtle pericardial tamponade physiology.
Bone marrow- or adipose-mesenchymal stromal cell secretome preserves myocardial transcriptome profile and ameliorates cardiac damage following ex vivo cold storage
(Elsevier, 2022) Scott, Susan R.; March, Keith L.; Wang, I-Wen; Singh, Kanhaiya; Liu, Jianyun; Turrentin, Mark; Sen, Chandan K.; Wang, Meijing; Surgery, School of Medicine
Background: Heart transplantation, a life-saving approach for patients with end-stage heart disease, is limited by shortage of donor organs. While prolonged storage provides more organs, it increases the extent of ischemia. Therefore, we seek to understand molecular mechanisms underlying pathophysiological changes of donor hearts during prolonged storage. Additionally, considering mesenchymal stromal cell (MSC)-derived paracrine protection, we aim to test if MSC secretome preserves myocardial transcriptome profile and whether MSC secretome from a certain source provides the optimal protection in donor hearts during cold storage. Methods and results: Isolated mouse hearts were divided into: no cold storage (control), 6 h cold storage (6 h-I), 6 h-I + conditioned media from bone marrow MSCs (BM-MSC CM), and 6 h-I + adipose-MSC CM (Ad-MSC CM). Deep RNA sequencing analysis revealed that compared to control, 6 h-I led to 266 differentially expressed genes, many of which were implicated in modulating mitochondrial performance, oxidative stress response, myocardial function, and apoptosis. BM-MSC CM and Ad-MSC CM restored these gene expression towards control. They also improved 6 h-I-induced myocardial functional depression, reduced inflammatory cytokine production, decreased apoptosis, and reduced myocardial H2O2. However, neither MSC-exosomes nor exosome-depleted CM recapitulated MSC CM-ameliorated apoptosis and CM-improved mitochondrial preservation during cold ischemia. Knockdown of Per2 by specific siRNA abolished MSC CM-mediated these protective effects in cardiomyocytes following 6 h cold storage. Conclusions: Our results demonstrated that using MSC secretome (BM-MSCs and Ad-MSCs) during prolonged cold storage confers preservation of the normal transcriptional "fingerprint", and reduces donor heart damage. MSC-released soluble factors and exosomes may synergistically act for donor heart protection.
Cannabis use and heart transplant listing: A survey of clinician practices
(Public Library of Science, 2024-12-12) Ilonze, Onyedika J.; Knapp, Shannon M.; Chernyak, Yelena; Page, Robert L., II; Boyd, LaKeisha J.; Mazimba, Sula; Raman, Subha V.; Enyi, Chioma O.; Allen, Larry A.; Breathett, Khadijah; Medicine, School of Medicine
No consensus exists for heart transplant listing for patients who use cannabis. We conducted a web-based survey to assess knowledge, and practice patterns towards patients with heart failure who use cannabis referred for transplant. A total of 140 clinicians (cardiologists (41.4%, n = 58), surgeons (7.1%, n = 10), pharmacists (9.3%, n = 13), advanced practice providers and coordinators) responded and responses were grouped by whether they responded that cannabis is "illegal in my state" (illegal), or "legal for medical and recreational use in my state," (legal). There was a statistically significant difference in responses between the groups in the frequency of cannabis use that should preclude a patient from HT listing p = 0.0330) with respondents where cannabis is legal tending to answer that higher frequencies were acceptable. The groups in the "legal group" responded that a validated cannabis screening questionnaire could evaluate HT eligibility (p = 0.0111). A majority in the illegal group responding "No" as to whether their program allows pre- or post-transplant patients to use prescribed cannabis products (p < 0.0001). A majority in the illegal group responding "No" while the majority in the legal group responded "Yes" to "Does your HT center's current selection criteria policy address medical cannabis use in potential transplant candidates?" (p = 0.0001). Health care providers generally agreed that a validated cannabis use disorder screening questionnaire would be useful and that 6 months of abstinence from cannabis is sufficient prior to HT listing. Significant heterogeneity exists regarding cannabis use as it relates to heart transplantation.
Computational pathology assessments of cardiac stromal remodeling: Clinical correlates and prognostic implications in heart transplantation
(Elsevier, 2024-12-28) Peyster, Eliot G.; Yuan, Cai; Arabyarmohammadi, Sara; Lal, Priti; Feldman, Michael D.; Fu, Pingfu; Margulies, Kenneth B.; Madabhushi, Anant; Pathology and Laboratory Medicine, School of Medicine
Background: The hostile immune environment created by allotransplantation can accelerate pathologic tissue remodeling. Both overt and indolent inflammatory insults propel this remodeling, but there is a paucity of tools for monitoring the speed and severity of remodeling over time. Methods: This retrospective cohort consisted of n = 2,167 digitized heart transplant biopsy slides along with records of prior inflammatory events and future allograft outcomes (cardiac death or allograft vasculopathy). Utilizing computational pathology analysis, biopsy images were analyzed to identify the pathologic stromal changes associated with future allograft loss or vasculopathy. Biopsy images were then analyzed to assess which historical inflammatory events drive progression of these pathologic stromal changes. Results: The top 5 features of pathologic stromal remodeling most associated with adverse allograft outcomes were also strongly associated with histories of both overt and indolent inflammatory events. Compared to controls, a history of high-grade or treated rejection was significantly associated with progressive pathologic remodeling and future adverse outcomes (32.9% vs 5.1%, p < 0.001). A history of recurrent low-grade rejection and Quilty lesions was also significantly associated with pathologic remodeling and adverse outcomes vs controls (12.7% vs 5.1%, p = 0.047). A history of high-grade or treated rejection in the absence of recurrent low-grade rejection history was not associated with pathologic remodeling or adverse outcomes (7.1% vs 5.1%, p = 0.67). Conclusions: A history of both traditionally treated and traditionally ignored alloimmune responses can predispose patients to pathologic allograft remodeling and adverse outcomes. Computational pathology analysis of allograft stroma yields translationally relevant biomarkers, identifying accelerated remodeling before adverse outcomes occur. Data availability: The data that support the findings of this study are presented in the manuscript and extended data sections. Unprocessed raw data are available from the corresponding author upon reasonable request. Source code for the stromal feature analysis pipeline is hosted on GitHub and freely available: https://github.service.emory.edu/CYUAN31/Pathomics_StromalBioMarker_in_Myocardium.git.
Donor Utilization in the Recent Era: Effect of Sex, Drugs, and Increased Risk
(American Heart Association, 2022) Baran, David A.; Long, Ashleigh; Lansinger, Justin; Copeland, Jack G.; Copeland, Hannah; Surgery, School of Medicine
Background: Heart transplantation volumes have increased in recent years, yet less than a third of donors are typically accepted for transplantation. Whether donor sex, donor drug use, or perception of increased risk affects utilization for transplantation is unclear. Methods: The United Network for Organ Sharing database was queried for donors from January 1, 2007, to December 31, 2017. Donor toxicology was collected when available. Multivariate analysis was conducted to examine correlations with donor utilization. Results: Between January 1, 2007, and December 31, 2017, there were 87 816 heart donors aged ≥15 years. The mean age was 42.7±15.8 years, and 24 831 donors (28.3%) were utilized for heart transplantation. Subsequent analyses focused on donors between 15 and 39 years old. The strongest associations with donor acceptance were for male donor sex, blood type, hepatitis C antibody, donor age, left ventricular hypertrophy, and history of donor drug use. After removing hepatitis C, Public Health Service Increased Risk was identified as a strong negative predictor. Most positive drug toxicology results were associated with donor nonuse except for donors between 15 and 19 years of age. Exceptions included alcohol, marijuana, and cocaine. Opiates were associated with less utilization at all donor ages. The Public Health Service Increased Risk status was associated with significantly less utilization in all age groups except 15- to 19-year-old donors. Conclusions: While male donors were preferentially utilized, donors with drug use or those deemed Public Health Service Increased Risk were significantly less utilized for heart transplantation. Further consideration of such donors would be appropriate particularly as the demand for transplantation continues to increase.
Group Dynamics and Allocation of Advanced Heart Failure Therapies-Heart Transplants and Ventricular Assist Devices-By Gender, Racial, and Ethnic Group
(American Heart Association, 2023) Breathett, Khadijah; Yee, Ryan; Pool, Natalie; Thomas Hebdon, Megan C.; Knapp, Shannon M.; Herrera-Theut, Kathryn; de Groot, Esther; Yee, Erika; Allen, Larry A.; Hasan, Ayesha; Lindenfeld, JoAnn; Calhoun, Elizabeth; Carnes, Molly; Sweitzer, Nancy K.; Medicine, School of Medicine
Background: US regulatory framework for advanced heart failure therapies (AHFT), ventricular assist devices, and heart transplants, delegate eligibility decisions to multidisciplinary groups at the center level. The subjective nature of decision‐making is at risk for racial, ethnic, and gender bias. We sought to determine how group dynamics impact allocation decision‐making by patient gender, racial, and ethnic group. Methods and Results: We performed a mixed‐methods study among 4 AHFT centers. For ≈ 1 month, AHFT meetings were audio recorded. Meeting transcripts were evaluated for group function scores using de Groot Critically Reflective Diagnoses protocol (metrics: challenging groupthink, critical opinion sharing, openness to mistakes, asking/giving feedback, and experimentation; scoring: 1 to 4 [high to low quality]). The relationship between summed group function scores and AHFT allocation was assessed via hierarchical logistic regression with patients nested within meetings nested within centers, and interaction effects of group function score with gender and race, adjusting for patient age and comorbidities. Among 87 patients (24% women, 66% White race) evaluated for AHFT, 57% of women, 38% of men, 44% of White race, and 40% of patients of color were allocated to AHFT. The interaction between group function score and allocation by patient gender was statistically significant (P=0.035); as group function scores improved, the probability of AHFT allocation increased for women and decreased for men, a pattern that was similar irrespective of racial and ethnic groups. Conclusions: Women evaluated for AHFT were more likely to receive AHFT when group decision‐making processes were of higher quality. Further investigation is needed to promote routine high‐quality group decision‐making and reduce known disparities in AHFT allocation.
Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African-American, Hispanic, and White Patients
(American Heart Association, 2021) Breathett, Khadijah; Knapp, Shannon M.; Carnes, Molly; Calhoun, Elizabeth; Sweitzer, Nancy K.; Medicine, School of Medicine
Imbalance in Heart Transplant to Heart Failure Mortality Ratio by Sex
(American Heart Association, 2021) Breathett, Khadijah; Knapp, Shannon M.; Carnes, Molly; Calhoun, Elizabeth; Sweitzer, Nancy K.; Medicine, School of Medicine
In-hospital complications associated with total artificial heart implantation in the United States between 2004 to 2011
(e-Century, 2022-10-15) Pasha, Ahmed K.; Lee, Justin Z.; Desai, Hem; Hashemzadeh, Mehrtash; Movahed, Mohammad Reza; Medicine, School of Medicine
Objective: Total artificial heart (TAH) utilization has increased over the recent years. The goal of this study was to evaluate the trend of artificial hearts used in the USA with its associated morbidity and mortality based on a large in-hospital database. Materials and methods: Using a very large nationwide inpatient samples (NIS) database, we used ICD-9 code for a total artificial heart. We evaluated the utilization of this device over the years studied. Furthermore, we evaluated any associated complications and mortality in patients receiving this device. Results: From 2004 until 2011, the rate of total artificial heart implants increased over the years from 5 in 2004 to the highest of 26 in 2011 across the United State. TAH was insesrted in 75 patients. Death was reported in 22 patients (29.3%). Acute renal failure was the most common complication (69.3%). This is followed by post-operative infectious complications (28.0%), acute renal failure requiring dialysis (16%), bleeding complications requiring blood transfusion (14.7%) respiratory complications (6.7%), and stroke/TIA (4.0%). There was no post-operative deep vein thrmobosis or pulmonary embolism. Conclusions: The use of total artificial heart has increased in the United State steadily with substantial morbidity and mortality associated with this device.
Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study
(Frontiers Media, 2022-06-09) Gökler, Johannes; Aliabadi-Zuckermann, Arezu Z.; Kaider, Alexandra; Ambardekar, Amrut V.; Antretter, Herwig; Artemiou, Panagiotis; Bertolotti, Alejandro M.; Boeken, Udo; Brossa, Vicens; Copeland, Hannah; Crespo-Leiro, Maria Generosa; Eixerés-Esteve, Andrea; Epailly, Eric; Farag, Mina; Hulman, Michal; Khush, Kiran K.; Masetti, Marco; Patel, Jignesh; Ross, Heather J.; Rudež, Igor; Silvestry, Scott; Martin Suarez, Sofia; Vest, Amanda; Zuckermann, Andreas O.; Surgery, School of Medicine
Background: Allograft pathologies, such as valvular, coronary artery, or aortic disease, may occur early and late after cardiac transplantation. Cardiac surgery after heart transplantation (CASH) may be an option to improve quality of life and allograft function and prolong survival. Experience with CASH, however, has been limited to single-center reports. Methods: We performed a retrospective, multicenter study of heart transplant recipients with CASH between January 1984 and December 2020. In this study, 60 high-volume cardiac transplant centers were invited to participate. Results: Data were available from 19 centers in North America (n = 7), South America (n = 1), and Europe (n = 11), with a total of 110 patients. A median of 3 (IQR 2-8.5) operations was reported by each center; five centers included ≥ 10 patients. Indications for CASH were valvular disease (n = 62), coronary artery disease (CAD) (n = 16), constrictive pericarditis (n = 17), aortic pathology (n = 13), and myxoma (n = 2). The median age at CASH was 57.7 (47.8-63.1) years, with a median time from transplant to CASH of 4.4 (1-9.6) years. Reoperation within the first year after transplantation was performed in 24.5%. In-hospital mortality was 9.1% (n = 10). 1-year survival was 86.2% and median follow-up was 8.2 (3.8-14.6) years. The most frequent perioperative complications were acute kidney injury and bleeding revision in 18 and 9.1%, respectively. Conclusion: Cardiac surgery after heart transplantation has low in-hospital mortality and postoperative complications in carefully selected patients. The incidence and type of CASH vary between international centers. Risk factors for the worse outcome are higher European System for Cardiac Operative Risk Evaluation (EuroSCORE II) and postoperative renal failure.

Browsing by Subject "Heart transplantation"

Results Per Page

Sort Options